Cahan 2015
Cahan 2015
Cahan 2015
3. Shah GD, DeAngelis LM. Treatment of primary central nervous upfront chemotherapy. Int J Radiat Oncol Biol Phys 2011;80:
system lymphoma. Hematol Oncol Clin North Am 2005;19. 611-27, v. 169-175.
4. DeAngelis LM, Seiferheld W, Schold SC, et al. Combination 7. Reni M, Ferreri AJ, Guha-Thakurta N, et al. Clinical relevance of
chemotherapy and radiotherapy for primary central nervous system consolidation radiotherapy and other main therapeutic issues in
lymphoma: Radiation Therapy Oncology Group Study 93-10. J Clin primary central nervous system lymphomas treated with upfront
Oncol 2002;20:4643-4648. high-dose methotrexate. Int J Radiat Oncol Biol Phys 2001;51:
5. Gavrilovic IT, Hormigo A, Yahalom J, et al. Long-term follow-up of 419-425.
high-dose methotrexate-based therapy with and without whole brain 8. Shah GD, Yahalom J, Correa DD, et al. Combined immunochemo-
irradiation for newly diagnosed primary CNS lymphoma. J Clin Oncol therapy with reduced whole-brain radiotherapy for newly diagnosed
2006;24:4570-4574. primary CNS lymphoma. J Clin Oncol 2007;25:4730-4735.
6. Ferreri AJ, Verona C, Politi LS, et al. Consolidation radiotherapy in 9. Korfel A, Thiel E, Martus P, et al. Randomized phase III study of
primary central nervous system lymphomas: Impact on outcome of whole-brain radiotherapy for primary CNS lymphoma. Neurology
different fields and doses in patients in complete remission after 2015;84:1242-1248.
ERRATUM
In the article referenced above, the affiliation for authors Fatima Munoz, MD, MPH, and Connie Lafuente, BA, should have
appeared as follows:
U.S.-Mexico Border Health Commission
The authors regret the error.
http://dx.doi.org/10.1016/j.ijrobp.2015.06.030